|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Supplemental Table 4: Effects of Raloxifene and/or Lovaza on Relative Plasma Fatty Acid Concentration | | | | | | | | | | | | | | | | |
|  |  | Groups | | | | | | | | | | | | | | |
| Plasma fatty acid | Time | Control  n=46 | | | Raloxifene  (60 mg)  n=38 | | | Raloxifene  (30 mg)  n=36 | | | Lovaza  (4 g)  n=48 | | | Lovaza (4 g)  Raloxifene (30 mg)  n=44 | | |
| C14:0 (*%)* | Baseline | 1.06 | ± | 0.46 | 1.04 | ± | 0.39 | 0.92 | ± | 0.31 | 1.04 | ± | 0.37 | 0.97 | ± | 0.41 |
| *Myristic* | 1 year | 1.14 | ± | 0.55 | 1.12 | ± | 0.44 | 1.00 | ± | 0.36 | 0.98 | ± | 0.48 | 0.94 | ± | 0.36 |
|  | 2 year | 1.02 | ± | 0.43 | 1.21 | ± | 0.30 | 0.99 | ± | 0.41 | 1.01 | ± | 0.39 | 0.95 | ± | 0.37 |
| C16:0 *(%)* | Baseline | 26.92 | ± | 2.64 | 27.38 | ± | 2.27 | 26.48 | ± | 2.21 | 26.27 | ± | 4.18 | 26.68 | ± | 2.14 |
| *Palmitic* | 1 year | 26.87 | ± | 2.56 | 28.43 | ± | 2.73 | 27.67 | ± | 2.12 | 26.51 | ± | 2.49 | 27.34 | ± | 2.34 |
|  | 2 year | 27.34 | ± | 2.22 | 28.93 | ± | 1.82 | 28.19 | ± | 2.59 | 27.49 | ± | 2.74 | 28.05 | ± | 2.23 |
| C16:1N7 (*%)* | Baseline | 2.48 | ± | 1.17 | 2.53 | ± | 0.99 | 2.50 | ± | 1.22 | 2.16 | ± | 0.67 | 2.03 | ± | 0.81 |
| *Palmitoleic* | 1 year | 2.35 | ± | 1.25 | 2.69 | ± | 1.37 | 2.85 | ± | 1.32 | 1.88 | ± | 0.75 | 1.96 | ± | 0.71 |
|  | 2 year | 2.32 | ± | 0.67 | 2.98 | ± | 1.06 | 2.76 | ± | 1.35 | 1.99 | ± | 0.62 | 2.20 | ± | 0.82 |
| C18:0 (*%)a,b* | Baseline | 9.45 | ± | 3.75 | 9.34 | ± | 3.18 | 8.12 | ± | 0.90 | 8.76 | ± | 2.21 | 9.61 | ± | 3.17 |
| *Steric* | 1 year | 9.45 | ± | 3.24 | 9.18 | ± | 3.14 | 8.29 | ± | 1.82 | 9.17 | ± | 2.91 | 9.40 | ± | 2.71 |
|  | 2 year | 10.34 | ± | 4.30 | 10.29 | ± | 3.77 | 9.63 | ± | 3.77 | 10.65 | ± | 4.44 | 10.16 | ± | 3.68 |
| C18:1N9 (*%)* | Baseline | 18.20 | ± | 2.80 | 18.45 | ± | 2.63 | 17.63 | ± | 2.90 | 18.10 | ± | 2.80 | 18.19 | ± | 2.29 |
| *Oleic* | 1 year | 17.80 | ± | 2.39 | 17.73 | ± | 2.40 | 18.12 | ± | 2.81 | 16.41 | ± | 2.32 | 16.28 | ± | 2.51 |
|  | 2 year | 19.16 | ± | 2.19 | 19.03 | ± | 2.11 | 19.07 | ± | 2.42 | 17.93 | ± | 2.31 | 17.34 | ± | 1.97 |
| C18:2N6 (*%)* | Baseline | 30.51 | ± | 5.37 | 29.54 | ± | 5.69 | 31.50 | ± | 3.74 | 32.42 | ± | 5.34 | 30.28 | ± | 5.27 |
| *Linoleic* | 1 year | 31.05 | ± | 5.53 | 28.90 | ± | 4.92 | 29.80 | ± | 4.79 | 31.04 | ± | 5.49 | 29.27 | ± | 4.69 |
|  | 2 year | 28.05 | ± | 5.59 | 25.99 | ± | 5.19 | 27.26 | ± | 6.33 | 28.36 | ± | 6.03 | 27.94 | ± | 5.22 |
| C18:3N3 (*%)* | Baseline | 0.64 | ± | 0.31 | 0.59 | ± | 0.33 | 0.76 | ± | 0.55 | 0.66 | ± | 0.50 | 0.54 | ± | 0.34 |
| *ALA* | 1 year | 0.65 | ± | 0.38 | 0.54 | ± | 0.30 | 0.70 | ± | 0.54 | 0.62 | ± | 0.38 | 0.60 | ± | 0.51 |
|  | 2 year | 0.49 | ± | 0.28 | 0.44 | ± | 0.23 | 0.54 | ± | 0.41 | 0.64 | ± | 0.52 | 0.50 | ± | 0.25 |
| C20:4N6 (*%) b* | Baseline | 6.72 | ± | 1.88 | 7.05 | ± | 1.75 | 7.41 | ± | 2.05 | 6.70 | ± | 1.54 | 6.98 | ± | 1.79 |
| *Arachidonic* | 1 year | 6.88 | ± | 1.99 | 6.93 | ± | 2.01 | 7.17 | ± | 2.12 | 5.41 | ± | 1.37 | 5.83 | ± | 1.56 |
|  | 2 year | 6.67 | ± | 2.01 | 6.44 | ± | 1.49 | 6.83 | ± | 2.01 | 5.00 | ± | 2.03 | 5.68 | ± | 1.54 |
| C20:5N3 (*%) b* | Baseline | 1.33 | ± | 0.66 | 1.34 | ± | 0.43 | 1.39 | ± | 0.64 | 1.19 | ± | 0.34 | 1.42 | ± | 0.60 |
| *EPA* | 1 year | 1.32 | ± | 0.42 | 1.38 | ± | 0.90 | 1.37 | ± | 0.88 | 3.32 | ± | 1.76 | 3.48 | ± | 2.01 |
|  | 2 year | 1.06 | ± | 0.60 | 0.97 | ± | 0.50 | 1.09 | ± | 0.80 | 2.94 | ± | 1.16 | 3.08 | ± | 1.09 |
| C22:5N3 (*%)b* | Baseline | 0.71 | ± | 0.36 | 0.59 | ± | 0.34 | 0.79 | ± | 0.38 | 0.78 | ± | 0.39 | 0.66 | ± | 0.35 |
| *DPA* | 1 year | 0.61 | ± | 0.37 | 0.63 | ± | 0.43 | 0.65 | ± | 0.31 | 0.94 | ± | 0.47 | 0.79 | ± | 0.38 |
|  | 2 year | 0.81 | ± | 0.38 | 0.74 | ± | 0.33 | 0.80 | ± | 0.39 | 1.08 | ± | 0.43 | 1.06 | ± | 0.43 |
| C22:6N3 (*%) b* | Baseline | 1.33 | ± | 0.55 | 1.38 | ± | 0.84 | 1.04 | ± | 0.66 | 1.30 | ± | 0.58 | 1.36 | ± | 0.54 |
| *DHA* | 1 year | 1.30 | ± | 0.63 | 1.26 | ± | 0.76 | 1.08 | ± | 0.61 | 2.91 | ± | 1.95 | 2.66 | ± | 0.85 |
|  | 2 year | 1.95 | ± | 0.89 | 1.90 | ± | 0.90 | 1.87 | ± | 0.98 | 3.22 | ± | 1.14 | 3.64 | ± | 1.15 |
| Saturated (*%)* | Baseline | 37.51 | ± | 6.02 | 37.43 | ± | 4.69 | 35.64 | ± | 2.42 | 36.03 | ± | 5.23 | 37.36 | ± | 4.76 |
|  | 1 year | 37.47 | ± | 5.40 | 38.73 | ± | 5.36 | 36.95 | ± | 2.77 | 36.66 | ± | 5.05 | 37.69 | ± | 4.55 |
|  | 2 year | 38.70 | ± | 6.27 | 40.43 | ± | 5.15 | 38.81 | ± | 5.84 | 39.15 | ± | 6.22 | 39.16 | ± | 5.65 |
| Mono-unsat. (*%)b* | Baseline | 20.77 | ± | 3.46 | 21.16 | ± | 3.75 | 19.94 | ± | 3.90 | 20.37 | ± | 3.44 | 20.16 | ± | 2.93 |
|  | 1 year | 20.17 | ± | 3.13 | 20.43 | ± | 3.46 | 20.90 | ± | 4.25 | 18.43 | ± | 3.06 | 18.18 | ± | 2.80 |
|  | 2 year | 21.64 | ± | 2.46 | 22.19 | ± | 2.75 | 21.99 | ± | 3.32 | 20.17 | ± | 2.69 | 19.72 | ± | 2.57 |
| N3 (*%)b* | Baseline | 4.09 | ± | 1.44 | 3.87 | ± | 1.07 | 4.04 | ± | 1.23 | 3.94 | ± | 1.02 | 4.03 | ± | 1.22 |
|  | 1 year | 3.91 | ± | 1.17 | 3.96 | ± | 1.65 | 3.93 | ± | 1.49 | 7.87 | ± | 2.85 | 7.66 | ± | 2.61 |
|  | 2 year | 4.43 | ± | 1.22 | 4.34 | ± | 1.16 | 4.46 | ± | 1.54 | 8.06 | ± | 1.96 | 8.42 | ± | 1.93 |
| N6 (*%)b* | Baseline | 37.15 | ± | 5.95 | 36.73 | ± | 6.61 | 38.99 | ± | 4.58 | 39.17 | ± | 5.81 | 37.24 | ± | 6.00 |
|  | 1 year | 37.93 | ± | 6.38 | 35.82 | ± | 6.24 | 36.97 | ± | 5.63 | 36.45 | ± | 5.83 | 35.10 | ± | 5.48 |
|  | 2 year | 34.72 | ± | 6.67 | 32.43 | ± | 6.12 | 34.09 | ± | 7.77 | 33.36 | ± | 6.83 | 33.62 | ± | 6.09 |
| *a*Significant Raloxifene effect (P<0.05)  *b*Significant Lovaza effect (P<0.05) | | | | | | | | | | | | | | | | |